Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials

BACKGROUND: Patients undergoing chemotherapy are known to be at risk for infection from myelosuppression by cytotoxic agents (CTAs) or immunosuppressive effects from mTOR inhibitors. The infection risk of newly developed anticancer agents has not been fully evaluated. It remains unknown how T-cell a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Kuchiba, Aya, Koyama, Takafumi, Machida, Ryunosuke, Shimomura, Akihiko, Kitano, Shigehisa, Shimizu, Toshio, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174012/
https://www.ncbi.nlm.nih.gov/pubmed/32276948
http://dx.doi.org/10.1136/esmoopen-2019-000653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174012/
https://www.ncbi.nlm.nih.gov/pubmed/32276948
http://dx.doi.org/10.1136/esmoopen-2019-000653

Ejemplares similares